相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis
Mwangi J. Murage et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2021)
Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a US commercially insured population
Bingcao Wu et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2021)
Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status
Steven R. Feldman et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2021)
Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center
Nahide Onsun et al.
DERMATOLOGIC THERAPY (2021)
Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States
Martin Bergman et al.
RHEUMATOLOGY AND THERAPY (2021)
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study
Tiago Torres et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)
Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis
Flavia Anghel et al.
LIFE-BASEL (2021)
Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis
Ahmed I. Mourad et al.
FRONTIERS IN MEDICINE (2021)
Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Z. Z. N. Yiu et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Ixekizumab for the treatment of psoriasis: up-to-date
Sarah Craig et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies
N. D. Loft et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation A Systematic Review and Meta-Analysis
Aya F. Ozaki et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2020)
Drug survival, discontinuation rates, and safety profile of secukinumab in real-world patients: a 152-week, multicenter, retrospective study
Ricardo Ruiz-Villaverde et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2020)
Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
Andrew Blauvelt et al.
PATIENT PREFERENCE AND ADHERENCE (2020)
National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study
Rosa Parisi et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Medication persistence of targeted immunomodulators for plaque psoriasis: A retrospective analysis using an US claims database
Nathaniel Hendrix et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis
S. K. Mahil et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Nonadherence to Treatment and Patient-Reported Outcomes of Psoriasis During the COVID-19 Epidemic: A Web-Based Survey
Qiaolin Wang et al.
PATIENT PREFERENCE AND ADHERENCE (2020)
Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting
Emanuela Zagni et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2020)
Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden
Kirk Geale et al.
RHEUMATOLOGY ADVANCES IN PRACTICE (2020)
The influence of body weight of patients with chronic plaque psoriasis on biological treatment response
Anna Kisielnicka et al.
POSTEPY DERMATOLOGII I ALERGOLOGII (2020)
Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naive patients from the French National Health Insurance database (SNIIRAM)
E. Sbidian et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity
Mwangi J. Murage et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2019)
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
Subrata Ghosh et al.
DRUG SAFETY (2019)
Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review
Shahnaz Khan et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2019)
Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis
Alexander Egeberg et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Drug Survival of Biological Therapies for Psoriasis Treatment in Germany and Associated Costs: A Retrospective Claims Database Analysis
Joerg Mahlich et al.
ADVANCES IN THERAPY (2019)
Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance
L. Ferrieres et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2019)
Psoriasis treatment patterns: a retrospective claims study
Sara Higa et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Comprehensive Study of Continuous Orthogonal Moments-A Systematic Review
Parminder Kaur et al.
ACM COMPUTING SURVEYS (2019)
Risk Factors for the Development of Psoriasis
Koji Kamiya et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
Laura M. Sawyer et al.
PLOS ONE (2019)
Aspects concerning patient adherence to anti-TNFα therapy in psoriasis: A decade of clinical experience
Madalina Mocanu et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2019)
How to perform a meta-analysis with R: a practical tutorial
Sara Balduzzi et al.
EVIDENCE-BASED MENTAL HEALTH (2019)
Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices
Luvneet Verma et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2018)
Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research
Toshihiro Ito et al.
JOURNAL OF DERMATOLOGY (2018)
Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis
Chong Won Choi et al.
ANNALS OF DERMATOLOGY (2018)
Characterization of adherence and persistence profile in a real-life population of patients treated with adalimumab
Omer Gendelman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Canada's Study of Adherence Outcomes in Patients Receiving Adalimumab: 3-year Results From the COMPANION Study
John K. Marshall et al.
CLINICAL THERAPEUTICS (2018)
Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?
Elizabeth N. Ergen et al.
EXPERIMENTAL DERMATOLOGY (2018)
Assessment of medication adherence and treatment satisfaction in Japanese patients with psoriasis of various severities
Susumu Ichiyama et al.
JOURNAL OF DERMATOLOGY (2018)
Differential Drug Survival of Second-line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Ireny Y. K. Iskandar et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength
Rachael J. Thorneloe et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Drug utilization patterns and adherence in patients on systemic medications for the treatment of psoriasis: A retrospective, comparative cohort study
Erica D. Dommasch et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis
Siddharth Singh et al.
PLOS ONE (2018)
Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the US Department of Defense Population
Seina Lee et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2018)
Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review
Mwangi J. Murage et al.
PATIENT PREFERENCE AND ADHERENCE (2018)
Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence
Pei-Tzu Lin et al.
SCIENTIFIC REPORTS (2018)
Adherence and resource use among psoriasis patients treated with biologics
Joseph S. Aleshaki et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2018)
Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization
April W. Armstrong et al.
BMC DERMATOLOGY (2018)
Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database
Rosarin Sruamsiri et al.
BMC DERMATOLOGY (2018)
Secukinumab in the treatment of psoriasis: patient selection and perspectives
Eric J. Yang et al.
PSORIASIS-TARGETS AND THERAPY (2018)
Predictors of long-term drug survival for infliximab in psoriasis
Q. Magis et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015
Toshinobu Matsui et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2017)
Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary
Lilla Pogacsas et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2017)
Evaluation of adherence predictors for the treatment of moderate to severe psoriasis with biologics: the importance of physician-patient interaction and communication
I. Zschocke et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials
William Malatestinic et al.
Journal of Managed Care & Specialty Pharmacy (2017)
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Emilie Sbidian et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective
Christopher Ross et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2016)
Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis
Arnd Jacobi et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2016)
Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis
Steven R. Feldman et al.
Journal of Managed Care & Specialty Pharmacy (2016)
A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients
Benjamin Chastek et al.
ADVANCES IN THERAPY (2016)
Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry
J. Zweegers et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Patient Adherence to Biologic Agents in Psoriasis
Der Yi Hsu et al.
DERMATOLOGY (2016)
Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study
Alessandro Giunta et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2016)
Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population
Jalpa A. Doshi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
A. Menter et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)
Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature
I. Belinchon et al.
PATIENT PREFERENCE AND ADHERENCE (2016)
Treatment of severe psoriasis with infliximab
Joyce Leman
Therapeutics and Clinical Risk Management (2016)
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis
P. Davila-Seijo et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Richard B. Warren et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis
Logan S. D'Souza et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis
Nicole C. Rouse et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2015)
Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris
R. Gniadecki et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis
Zhun Cao et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2015)
Treatment patterns with topicals, traditional systemics and biologics in psoriasis - a Swedish database analysis
A. Svedbom et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry
J. M. P. A. van den Reek et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Impact of obesity on the efficacy of ustekinumab in Japanese patients with psoriasis: a retrospective cohort study of 111 patients
Koichi Yanaba et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2014)
Treatment Adherence to Different Etanercept Regimens, Continuous vs. Intermittent, in Patients Affected by Plaque-Type Psoriasis
Maria Esposito et al.
DRUG DEVELOPMENT RESEARCH (2014)
Treatment patterns and therapy effectiveness in psoriasis patients initiating biologic therapy in England
Javaria Mona Khalid et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2014)
Treatment Patterns and Annual Drug Costs of Biologic Therapies Across Indications from the Humana Commercial Database
Andrew Howe et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2014)
Efficacy and Cost-Efficacy of Biologic Therapies for Moderate to Severe Psoriasis: A Meta-Analysis and Cost-Efficacy Analysis Using the Intention-to-Treat Principle
Ching-Chi Chi et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Economics of Non-Adherence to Biologic Therapies in Rheumatoid Arthritis
Mary A. De Vera et al.
CURRENT RHEUMATOLOGY REPORTS (2014)
Group-based trajectory modeling to assess adherence to biologics among patients with psoriasis
Yunfeng Li et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2014)
Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study
Luca Degli Esposti et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2014)
Survival rate of antitumour necrosis factor- treatments for psoriasis in routine dermatological practice: a multicentre observational study
M. Esposito et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities
Sue Ann Chan et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2013)
Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population
Benjamin Chastek et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2013)
Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting
Machaon Bonafede et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2013)
Drug survival rates in patients with psoriasis after treatment with biologics
Yoshinori Umezawa et al.
JOURNAL OF DERMATOLOGY (2013)
Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis
Howa Yeung et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Standardizing Terminology and Definitions of Medication Adherence and Persistence in Research Employing Electronic Databases
Marsha A. Raebel et al.
MEDICAL CARE (2013)
Treatment Patterns in the First Year After Initiating Tumor Necrosis Factor Blockers in Real-World Settings
Machaon Bonafede et al.
ADVANCES IN THERAPY (2012)
Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Etanercept: efficacy and safety for approved indications
Todd A. Kerensky et al.
EXPERT OPINION ON DRUG SAFETY (2012)
Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement
Damian Hoy et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2012)
Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis
Vito Di Lernia et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2012)
Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris
R. Gniadecki et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Responses to ustekinumab in the anti-TNF agent-naive vs. anti-TNF agent-exposed patients with psoriasis vulgaris
A. Clemmensen et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls
Leia C. R. Silva et al.
IMMUNOTHERAPY (2010)
The immunogenicity of humanized and fully human antibodies Residual immunogenicity resides in the CDR regions
Fiona A. Harding et al.
MABS (2010)
The safety and side effects of monoclonal antibodies
Trevor T. Hansel et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis
Monali J. Bhosle et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2006)
Quality of life in patients with psoriasis
Monali J. Bhosle et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2006)
Psoriasis induced by anti-tumor necrosis factor therapy - A paradoxical adverse reaction
PP Sfikakis et al.
ARTHRITIS AND RHEUMATISM (2005)
Systemic treatment for moderate to severe psoriasis: Estimates of failure rates and direct medical costs in a north-eastern US managed care plan
SR Feldman et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2005)
分享论文
